Antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Waters, Valerie ^a   Ratjen, F ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE EXACERBATION; FOLLOW UP; GRAM NEGATIVE INFECTION; HUMAN; OUTCOME ASSESSMENT; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; REVIEW; CHRONIC DISEASE; DRUG COMBINATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; ALLERGIC RASH; BACTERIUM ISOLATE; CHRONIC LUNG DISEASE; COLONY FORMING UNIT; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FORCED EXPIRATORY VOLUME; HAZARD RATIO; HEPATITIS; HOSPITALIZATION; HOST SUSCEPTIBILITY; IN VITRO STUDY; LENGTH OF STAY; LUNG FUNCTION; META ANALYSIS; MORTALITY; PROSPECTIVE STUDY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SWEAT TEST; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 44949113364     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006961     Document Type: Review

References (25)

1. Aaron 2000 Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. American Journal of Respiratory and Critical Care Medicine 2000;161(4 Pt 1):1206-12.
2. Aaron 2005 Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al.Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;366(9484):463-71.
3. Burns 2001 Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al.Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. Journal of Infectious Diseases 2001;183(3):444-52.
4. Ceri 1999 Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. Journal of Clinical Microbiology 1999;37(6):1771-6.
5. Donner 2001 Donner A, Piaggio G, Villar J. Statistical methods for the meta-analysis of cluster randomized trials. Statistical Methods in Medical Research 2001;10(5):325-38.
6. Drenkard 2002 Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416(6882):740-3.
7. Foweraker 2005 Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. Journal of Antimicrobial Chemotherapy 2005;55(6):921-7.
8. Gaillard 1995 Gaillard JL, Cahen P, Delacourt C, Silly C, Le Bourgeois M, Coustère C, et al.Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 1995;14(4):291-6.
9. Gibson 2003 Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(8):918-51.
10. Henry 1992 Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatric Pulmonology 1992;12(3):158-61.
11. Higgins 2003 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60.
12. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
13. Jüni 2001 Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
14. Kosorok 2001 Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al.Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatric Pulmonology 2001;32(4):277-87.
15. Lee 2003 Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of cystic fibrosis 2003;2(1):29- 34.
16. Moskowitz 2004 Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Journal of Clinical Microbiology 2004;42(5):1915-22.
17. Moskowitz 2005 Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. Journal of Antimicrobial Chemotherapy 2005;56(5):879-86.
18. Pamukcu 1995 Pamukcu A, Bush A, Buchdahl R. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatric Pulmonology 1995;19(1): 10-5.
19. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
20. Prince 2002 Prince AS. Biofilms, antimicrobial resistance, and airway infection. The New England Journal of Medicine 2002;347(14):1110-1.
21. Rosenfeld 2001 Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al.Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 2001;139(3):359-65.
22. Saiman 1996 Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(3):532-7.
23. Singh 2000 Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407(6805):762-4.
24. Smith 1999 Smith AL, Doershuk C, Goldman D, Gore E, Hilman B, Marks M, et al.Comparison of a B-lactam alone versus B-lactam and an aminoglycoside for a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 1999;134(4):413-21.
25. Smith 2003 Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123(5):1495-502.